Short communicationMilnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Section snippets
Methods and materials
Assays and data analyses were performed as previously described in detail Owens et al., 1997, Owens et al., 2001. All competition assays utilized 12 concentrations of competing ligands in triplicate samples over a maximum concentration range of 10−13 to 10−4.67 mol/L. The chosen concentration of competing ligands was adjusted for each assay. For uptake assays, cells were incubated with competing ligand for 10 minutes before addition of radiolabeled transmitter. After 10 minutes of incubation
Results
Table 1 lists the affinities (Ki; nmol/L) of the various antidepressants for the transporters assayed. All data are shown as geometric mean ± SE in nmol/L. Milnacipran bound to both serotonin and norepinephrine transporters with high affinity (Ki = 8.44 and 22 nmol/L, respectively), as did duloxetine, amitriptyline, and nortriptyline (Ki < 20 nmol/L in all cases). Venlafaxine and citalopram, in contrast, selectively bound to the SERT, but not the norepinephrine transporter (NET), with high
Discussion
The binding affinity of a drug for various transporters and/or receptors can theoretically predict both clinical efficacy and side effect profile. Potent antagonists of SERTs or NETs (or both) are clinically effective antidepressants. In agreement with previous in vitro human monoamine transporter studies, all drugs tested were potent antagonists of the SERT Owens et al., 2001, Tatsumi et al., 1997, Moret et al., 1985. Though the relevance of dopamine transporter (DAT) inhibition to
Acknowledgements
This research was supported by a research grant from Cypress Biosciences, San Diego, California.
Dr. Nemeroff is a paid consultant and stockholder of Cypress Biosciences. Drs. Rao and Kranzler are employees of Cypress Biosciences. At the time the research was performed, Dr. Owens was also a consultant for Cypress Biosciences; however, he is no longer a consultant at this time or at the time the manuscript was submitted.
References (15)
- et al.
Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
Eur J Pharmacol
(1998) - et al.
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
Neuropsychopharmacology
(2001) - et al.
Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor
Neuropsychopharmacology
(1995) - et al.
Effect of acute, short- and long-term milnacipran administration on rat locus caeruleus noradrenergic and dorsal raphe serotonergic neurons
Neuropharmacology
(1998) - et al.
Biochemical profile of midalcipran (F 2207),1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug
Neuropharmacology
(1985) - et al.
Second-generation SSRIsHuman monoamine transporter binding profile of escitalopram and R-fluoxetine
Biol Psychiatry
(2001) - et al.
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Eur J Pharmacol
(1997)
Cited by (144)
Promising new pharmacological targets for depression: The search for efficacy
2023, Drug Discovery TodayDesign, synthesis and cytotoxic evaluation of a selective serotonin reuptake inhibitor (SSRI) by virtual screening
2023, European Journal of Pharmaceutical SciencesEmotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder
2022, Journal of Affective DisordersCitation Excerpt :One might argue that norepinephrine reuptake with venlafaxine could mitigate emotional blunting, thus it was not an ideal comparator for bupropion. However, this notion would be inconsistent with a recent survey reporting that duloxetine was associated with emotional blunting more frequently than venlafaxine (Goodwin et al., 2017) despite duloxetine having a higher relative affinity for the norepinephrine transporter (Bymaster et al., 2001; Vaishnavi et al., 2004). Furthermore, the venlafaxine doses used here were primarily inhibiting serotonin reuptake, likely at or near maximum occupancy (Debonnel et al., 2007; Meyer et al., 2004; Owens et al., 2008).
Attention Deficit Hyperactivity Disorder
2022, Comprehensive PharmacologyCombining antidepressants to address treatment-resistant depression
2022, Managing Treatment-Resistant Depression: Road to Novel Therapeutics6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation
2021, European Journal of Pharmacology